Calidi Biotherapeutics, Inc. (CLDI)

NYSEAMERICAN: CLDI · Real-Time Price · USD
1.650
-0.060 (-3.51%)
Aug 29, 2025, 4:00 PM - Market closed
-3.51%
Market Cap6.40M
Revenue (ttm)n/a
Net Income (ttm)-23.19M
Shares Out 3.88M
EPS (ttm)-33.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume313,176
Open1.710
Previous Close1.710
Day's Range1.590 - 1.740
52-Week Range1.540 - 46.680
Beta1.16
Analystsn/a
Price Targetn/a
Earnings DateAug 8, 2025

About CLDI

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clini... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 28
Stock Exchange NYSEAMERICAN
Ticker Symbol CLDI
Full Company Profile

Financial Performance

Financial Statements

News

Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of target...

9 days ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering

SAN DIEGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of target...

10 days ago - GlobeNewsWire

Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights

SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with ...

22 days ago - GlobeNewsWire

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of target...

5 weeks ago - GlobeNewsWire

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on July 24

SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of target...

5 weeks ago - GlobeNewsWire

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one...

7 weeks ago - GlobeNewsWire

Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds

SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of target...

7 weeks ago - GlobeNewsWire

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Calidi Biotherapeutics Inc. (NYSE American: CLDI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one...

7 weeks ago - GlobeNewsWire

Calidi Biotherapeutics Announces Shareholder Letter from CEO

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targe...

2 months ago - GlobeNewsWire

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor vir...

4 months ago - GlobeNewsWire

Global X Offers Precise U.S. Equity Exposure with Launch of Domestic Focused Funds

NEW YORK, April 16, 2025 /PRNewswire/ -- Global X Management Company LLC ("Global X"), the New York-based provider of exchange-traded funds (ETFs), today announced expanded access to U.S. equities wit...

4 months ago - PRNewsWire

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targ...

5 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targ...

5 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Demonstrated Ability To Deliver Transient Gene Therapy (Payload) To Tumors Using Systemic Platform

SAN DIEGO, March 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor vir...

6 months ago - GlobeNewsWire

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the ...

Other symbols: OSTX
6 months ago - Accesswire

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

6 months ago - GlobeNewsWire

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on February 5

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

7 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Bolstered Cash Balance and Termination of its Standby Equity Purchase Agreement

SAN DIEGO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

7 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

8 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $4.25 Million Public Offering of Common Stock

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targe...

8 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Proposed Public Offering

SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targe...

8 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

10 months ago - GlobeNewsWire

Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targe...

10 months ago - GlobeNewsWire

Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results

SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor viro...

10 months ago - GlobeNewsWire

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESSWIRE / October 25, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Smal...

Other symbols: NXL
11 months ago - Accesswire